Langer et al. [148] proved younger (<60 years) CN-AML patients with BAALC overexpression presented distinct gene expression signature, with upregulation of genes earlier associated with poor outcome (e.g., HGF, MN1, CD200), genes involved in drug resistance (e.g., ABCB1 alias MDR1) and hematopoietic stem-cell markers (PROM1 alias CD133, CD34, KIT). CD133 was the most upregulated gene in high BAALC expressers. The gene discussed is ABCB1; the disease is acute myeloid leukemia.